Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy Meeting Abstract
| Authors: | Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; Schiller, G. J.; Hu, B.; Volkert, A.; Gausman, J. A.; Hodgson, G.; Roth, D. A.; Warlick, E. D.; Kelly, M. J.; Stein, E. |
| Abstract Title: | Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 3333 |
| End Page: | 3335 |
| Language: | English |
| ACCESSION: | WOS:000893223203162 |
| DOI: | 10.1182/blood-2022-156564 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
